IOK Therapy for PTSD
(IOK Trial)
Trial Summary
What is the purpose of this trial?
The objective of this project is to test the efficacy of an individual treatment for post-traumatic stress disorder (PTSD) stemming from moral injury called Impact of Killing (IOK), compared to a present-centered therapy (PCT) control condition, and to determine the rehabilitative utility of IOK for Veterans with PTSD. The first aim is to test whether IOK can help improve psychosocial functioning for Veterans, as well as PTSD symptoms. The second aim is to determine whether IOK gains made by Veterans in treatment are durable, as measured by a six-month follow-up assessment. Veterans who kill in war are at increased risk for functional difficulties, PTSD, alcohol abuse, and suicide. Even after current PTSD psychotherapies, most Veterans continue to meet diagnostic criteria for PTSD, highlighting the need for expanding treatments for PTSD and functioning. IOK is a treatment that can be provided following existing PTSD treatments, filling a critical gap for Veterans with moral injury who continue to suffer from mental health symptoms and functional difficulties.
Research Team
Shira Maguen, PhD
Principal Investigator
San Francisco VA Medical Center, San Francisco, CA
Eligibility Criteria
This trial is for Veterans aged 18-82 with PTSD related to moral injury from killing in war. They must have completed or be stable on PTSD treatments like CPT or PE, and not changing medications during the study. Those with recent severe mental health issues, substance dependence, or active suicidal behaviors cannot join.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Impact of Killing (IOK) (Behavioral Intervention)
- Present Centered Therapy (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor
Dr. Grant Huang
VA Office of Research and Development
Acting Chief Research and Development Officer
PhD in Medical Psychology and Master of Public Health from the Uniformed Services University of Health Sciences
Dr. Erica M. Scavella
VA Office of Research and Development
Chief Medical Officer since 2022
MD from University of Massachusetts School of Medicine